Benefits of SMS for trial recruitment are self-evident, says Axiom

By Gareth Macdonald

- Last updated on GMT

Related tags: Contract research organisation

Axiom Accelerated Patient Recruitment hopes its new range of SMS, text messaging, services can help CROs and pharma sponsors reach more potential study participants.

Recruitment and retention are a perennial problem for the trials sector, causing contract research organisation (CRO) to continually seek out new ways of reaching and maintaining contact with patients.

In the last few months a number of companies, notably CenterWatch, TrialX, goBalto and Pfizer through its partnership with Private Access, have set up online systems to connect CROs with patients to help address the issue.

However, such methods do not address the problem of contacting patients who do not have internet access or indeed the difficulties associated with maintaining lines of communication during ongoing trials.

Julie Oimoen, project manager at Axiom, said the firm's new service is designed to address these difficulties and explained that the short message service (SMS) will be provided to clients for two specific applications.

She told Outsourcing-pharma that: “For patient recruitment, this will initially be directed to the younger populations for study specific requirements. Healthy subjects, 18 -35 years of age would be a good example of a potential audience.

“For patient retention during the course of a study, text messaging will be used for such things as appointment reminders, treatment reminders and things such as well being updates.”

She also stressed the approach has a global reach, and explained that: “Use of SMS technologies is far more advanced outside of the US, so we hope to capitalize on both markets. Huge population centres such as India, Latin America and China are emerging markets where adaptation of this technology is growing​.”

Social networking

Initially, potential study subjects will have to opt-in to the scheme and report a particular ailment or condition they have. However, Axiom also plans to use a range of marketing and web 2.0 approaches to access new patients as Oimoen explained.

We will reach this potential audience through traditional methods of outreach such as media advertising, referral networks and web optimization.

We will also use sources such as social networks and ailment specific communities to reach new potential subjects. This allows for opt-in, permission based contact​.”

Nevertheless Axiom is realistic about the services’ potential and the time it will take to build momentum. “As with any emerging technology, forecasting the level of demand is dependent upon many factors.

Some markets won’t apply, some potential patient populations may not grasp this technology, not to mention regulations are still being developed for this. Much like the adoption of email, we perceive the use of SMS to grow steadily for the right audience.

Related news

Show more

Related products

show more

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more